These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30596709)

  • 61. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
    Dorey L; Pelligand L; Lees P
    BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Deletion of the vacJ gene affects the biology and virulence in Haemophilus parasuis serovar 5.
    Zhao L; Gao X; Liu C; Lv X; Jiang N; Zheng S
    Gene; 2017 Mar; 603():42-53. PubMed ID: 27988234
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuis.
    Zhang P; Hao H; Li J; Ahmad I; Cheng G; Chen D; Tao Y; Huang L; Wang Y; Dai M; Liu Z; Yuan Z
    Front Microbiol; 2016; 7():385. PubMed ID: 27047487
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Colonization capacity and serum bactericidal activity of Haemophilus parasuis thy mutants.
    Bigas A; Garrido ME; Badiola I; Barbé J; Llagostera M
    Int Microbiol; 2006 Dec; 9(4):297-301. PubMed ID: 17236164
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of tulathromycin in the treatment of bovine respiratory disease associated with induced Mycoplasma bovis infections in young dairy calves.
    Godinho KS; Rae A; Windsor GD; Tilt N; Rowan TG; Sunderland SJ
    Vet Ther; 2005; 6(2):96-112. PubMed ID: 16094558
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunomodulatory effects of tulathromycin on apoptosis, efferocytosis, and proinflammatory leukotriene B4 production in leukocytes from Actinobacillus pleuropneumoniae-or zymosan-challenged pigs.
    Duquette SC; Fischer CD; Williams AC; Sajedy S; Feener TD; Bhargava A; Reti KL; Muench GP; Morck DW; Allison J; Lucas MJ; Buret AG
    Am J Vet Res; 2015 Jun; 76(6):507-19. PubMed ID: 26000598
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves.
    Balaje RM; Sidhu PK; Kaur G; Rampal S
    Res Vet Sci; 2013 Dec; 95(3):1114-24. PubMed ID: 23941961
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of enrofloxacin on Haemophilus parasuis infection, disease and immune response.
    Macedo N; Cheeran MC; Rovira A; Holtcamp A; Torremorell M
    Vet Microbiol; 2017 Feb; 199():91-99. PubMed ID: 28110792
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of antimicrobial activity against Mycoplasma mycoides subsp. mycoides Small Colony using an in vitro dynamic dilution pharmacokinetic/pharmacodynamic model.
    Mitchell JD; McKellar QA; McKeever DJ
    J Med Microbiol; 2013 Jan; 62(Pt 1):56-61. PubMed ID: 23002064
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Development of a physiologically based pharmacokinetic model to predict tulathromycin distribution in goats.
    Leavens TL; Tell LA; Clothier KA; Griffith RW; Baynes RE; Riviere JE
    J Vet Pharmacol Ther; 2012 Apr; 35(2):121-31. PubMed ID: 21671946
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prior infection with Bordetella bronchiseptica increases nasal colonization by Haemophilus parasuis in swine.
    Brockmeier SL
    Vet Microbiol; 2004 Mar; 99(1):75-8. PubMed ID: 15019114
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
    Dorey L; Pelligand L; Cheng Z; Lees P
    PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetic/pharmacodynamic modeling for concentration-dependent bactericidal activity of a bicyclolide, modithromycin.
    Katsube T; Wajima T; Yamano Y; Yano Y
    J Pharm Sci; 2014 Apr; 103(4):1288-97. PubMed ID: 24523230
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Emergence and Mechanism of Resistance of Tulathromycin Against
    Xia X; Yang L; Ling Y; Yu J; Ding H
    Front Vet Sci; 2022; 9():801800. PubMed ID: 35224081
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Haemophilus parasuis infection activates the NF-κB pathway in PK-15 cells through IκB degradation.
    Chen Y; Jin H; Chen P; Li Z; Meng X; Liu M; Li S; Shi D; Xiao Y; Wang X; Zhou Z; Bi D; Zhou R
    Vet Microbiol; 2012 Nov; 160(1-2):259-63. PubMed ID: 22704560
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against
    Yao L; Yang L; Ling Y; Wei Y; Shen X; Ding H
    Front Vet Sci; 2022; 9():822432. PubMed ID: 35419449
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Whole Genome Sequence Analysis of Pig Respiratory Bacterial Pathogens with Elevated Minimum Inhibitory Concentrations for Macrolides.
    Dayao DA; Seddon JM; Gibson JS; Blackall PJ; Turni C
    Microb Drug Resist; 2016 Oct; 22(7):531-537. PubMed ID: 26981707
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of bovine respiratory disease on the pharmacokinetics of danofloxacin and tulathromycin in different ages of calves.
    Mzyk DA; Bublitz CM; Martinez MN; Davis JL; Baynes RE; Smith GW
    PLoS One; 2019; 14(6):e0218864. PubMed ID: 31233558
    [TBL] [Abstract][Full Text] [Related]  

  • 79. How can we predict bacterial eradication?
    Jacobs MR
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Serum-resistance in Haemophilus parasuis is associated with systemic disease in swine.
    Cerdà-Cuéllar M; Aragon V
    Vet J; 2008 Mar; 175(3):384-9. PubMed ID: 17368943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.